ABSTRACT
Peptides for Optical Molecular Imaging – and the Real-time in situ Detection of Bacteria in Man
A formidable challenge in modern respiratory healthcare is the accurate and timely diagnosis of lung infection and inflammation. The EPSRC Interdisciplinary Research Collaboration (IRC) ‘Proteus’ seeks to address this challenge by developing an optical fibre based healthcare technology platform that combines physiological sensing with multiplexed optical molecular imaging. This technology enables in situ measurements in the distal lung to assess tissue function in health as well as generate and characterise unique signatures of pulmonary disease.
In my talk I will describe the chemistry behind the teams optical imaging probes. The peptide based probes we have developed are often synthetically challenging and range from highly branched small peptides that contain some 15 arginine residues to peptides that carry some 9 fluorophores. I will illustrate the in vivo application of four of these peptide-based materials that allow the detection of bacterial infection deep in the human lung the analysis of fibrosis and the detection of activated neutrophils. These reagents have also been used in conjunction with drugs to show in vivo target engagement in real-time in patients.
BIO
Mark Bradley did his PhD at the University of Oxford, followed by post-doctorial studies at Harvard Medical School before being appointed a Royal Society University Research Fellowship. He was awarded a Professorship in Combinatorial Chemistry in 1996 aged 34. He has been awarded a number of prizes including the Novartis Lectureship and the 2015 RSC Tilden Prize. He holds an ERC Advanced grant.
Mark is director of Proteus an Interdisciplinary Research Collaboration supported by the EPSRC that links together disciplines such as optical physics, chemistry, biology and engineering driven by clinical pull. He has published >300 peer reviewed papers, filed some 20 patents and is co-founder of Ilika (IPO 2010), DestiNA and Edinburgh Molecular Imaging.
Peptides for Optical Molecular Imaging – and the Real-time in situ Detection of Bacteria in Man
A formidable challenge in modern respiratory healthcare is the accurate and timely diagnosis of lung infection and inflammation. The EPSRC Interdisciplinary Research Collaboration (IRC) ‘Proteus’ seeks to address this challenge by developing an optical fibre based healthcare technology platform that combines physiological sensing with multiplexed optical molecular imaging. This technology enables in situ measurements in the distal lung to assess tissue function in health as well as generate and characterise unique signatures of pulmonary disease.
In my talk I will describe the chemistry behind the teams optical imaging probes. The peptide based probes we have developed are often synthetically challenging and range from highly branched small peptides that contain some 15 arginine residues to peptides that carry some 9 fluorophores. I will illustrate the in vivo application of four of these peptide-based materials that allow the detection of bacterial infection deep in the human lung the analysis of fibrosis and the detection of activated neutrophils. These reagents have also been used in conjunction with drugs to show in vivo target engagement in real-time in patients.
BIO
Mark Bradley did his PhD at the University of Oxford, followed by post-doctorial studies at Harvard Medical School before being appointed a Royal Society University Research Fellowship. He was awarded a Professorship in Combinatorial Chemistry in 1996 aged 34. He has been awarded a number of prizes including the Novartis Lectureship and the 2015 RSC Tilden Prize. He holds an ERC Advanced grant.
Mark is director of Proteus an Interdisciplinary Research Collaboration supported by the EPSRC that links together disciplines such as optical physics, chemistry, biology and engineering driven by clinical pull. He has published >300 peer reviewed papers, filed some 20 patents and is co-founder of Ilika (IPO 2010), DestiNA and Edinburgh Molecular Imaging.